File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Severe acute respiratory syndrome

TitleSevere acute respiratory syndrome
Authors
KeywordsClinical features
Coronavirus
Diagnosis
Epidemic
Prevention
Radiology
SARS
Issue Date2003
PublisherInternational Union against Tuberculosis and Lung Disease. The Journal's web site is located at http://www.theunion.org/about-the-journal/about-the-journal.html
Citation
International Journal Of Tuberculosis And Lung Disease, 2003, v. 7 n. 12, p. 1117-1130 How to Cite?
AbstractSevere acute respiratory syndrome (SARS) is a new disease that poses a threat to international health. The SARS epidemic earlier this year affected more than 30 countries and regions, with a cumulative global total of 8098 cases. It is caused by a novel coronavirus, probably of animal origin. The mean incubation period is 6.4 days (range 2-11 days). Patients usually present with high fever, chills, myalgia and dry cough, with or without chest X-ray evidence of pneumonia at the onset of disease. A history of contact with or travel to an area with local transmission is common. Diagnosis is based on clinical criteria, as a valid rapid diagnostic test is not yet available. There is no specific antiviral therapy for this disease, and no controlled clinical trial for any treatment modality has been conducted. In several retrospective studies steroids have been shown to be useful in a proportion of patients who deteriorated despite antibiotics and supportive treatment. SARS has a high morbidity (about 25% required intensive care) and fatality (9.6%). A high index of suspicion for the disease, isolation of patients, strict observation of infection control practices and compliance with use of personal protective equipment are necessary to prevent nosocomial infection. Contact tracing and quarantine are essential measures to prevent community spread of disease. Prevention of future outbreaks requires strengthening of infection control practices in hospitals, development of a rapid diagnostic test and a vaccine, and removal of any animal reservoir and environmental conditions that led to the spread of the disease.
Persistent Identifierhttp://hdl.handle.net/10722/157379
ISSN
2023 Impact Factor: 3.4
2023 SCImago Journal Rankings: 0.952
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChanYeung, Men_US
dc.contributor.authorOoi, GCen_US
dc.contributor.authorHui, DSen_US
dc.contributor.authorHo, PLen_US
dc.contributor.authorTsang, KWen_US
dc.date.accessioned2012-08-08T08:49:28Z-
dc.date.available2012-08-08T08:49:28Z-
dc.date.issued2003en_US
dc.identifier.citationInternational Journal Of Tuberculosis And Lung Disease, 2003, v. 7 n. 12, p. 1117-1130en_US
dc.identifier.issn1027-3719en_US
dc.identifier.urihttp://hdl.handle.net/10722/157379-
dc.description.abstractSevere acute respiratory syndrome (SARS) is a new disease that poses a threat to international health. The SARS epidemic earlier this year affected more than 30 countries and regions, with a cumulative global total of 8098 cases. It is caused by a novel coronavirus, probably of animal origin. The mean incubation period is 6.4 days (range 2-11 days). Patients usually present with high fever, chills, myalgia and dry cough, with or without chest X-ray evidence of pneumonia at the onset of disease. A history of contact with or travel to an area with local transmission is common. Diagnosis is based on clinical criteria, as a valid rapid diagnostic test is not yet available. There is no specific antiviral therapy for this disease, and no controlled clinical trial for any treatment modality has been conducted. In several retrospective studies steroids have been shown to be useful in a proportion of patients who deteriorated despite antibiotics and supportive treatment. SARS has a high morbidity (about 25% required intensive care) and fatality (9.6%). A high index of suspicion for the disease, isolation of patients, strict observation of infection control practices and compliance with use of personal protective equipment are necessary to prevent nosocomial infection. Contact tracing and quarantine are essential measures to prevent community spread of disease. Prevention of future outbreaks requires strengthening of infection control practices in hospitals, development of a rapid diagnostic test and a vaccine, and removal of any animal reservoir and environmental conditions that led to the spread of the disease.en_US
dc.languageengen_US
dc.publisherInternational Union against Tuberculosis and Lung Disease. The Journal's web site is located at http://www.theunion.org/about-the-journal/about-the-journal.htmlen_US
dc.relation.ispartofInternational Journal of Tuberculosis and Lung Diseaseen_US
dc.subjectClinical features-
dc.subjectCoronavirus-
dc.subjectDiagnosis-
dc.subjectEpidemic-
dc.subjectPrevention-
dc.subjectRadiology-
dc.subjectSARS-
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAge Distributionen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshChina - Epidemiologyen_US
dc.subject.meshCommunicable Diseases, Emerging - Prevention & Controlen_US
dc.subject.meshDisease Outbreaksen_US
dc.subject.meshDisease Transmission, Infectious - Prevention & Controlen_US
dc.subject.meshFemaleen_US
dc.subject.meshHong Kong - Epidemiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshQuarantine - Organization & Administrationen_US
dc.subject.meshRisk Assessmenten_US
dc.subject.meshSevere Acute Respiratory Syndrome - Drug Therapy - Epidemiology - Prevention & Controlen_US
dc.subject.meshSex Distributionen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshWorld Healthen_US
dc.titleSevere acute respiratory syndromeen_US
dc.typeArticleen_US
dc.identifier.emailHo, PL:plho@hkucc.hku.hken_US
dc.identifier.authorityHo, PL=rp00406en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid14677886-
dc.identifier.scopuseid_2-s2.0-0345733808en_US
dc.identifier.hkuros86275-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0345733808&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume7en_US
dc.identifier.issue12en_US
dc.identifier.spage1117en_US
dc.identifier.epage1130en_US
dc.identifier.isiWOS:000187029800003-
dc.publisher.placeFranceen_US
dc.identifier.scopusauthoridChanYeung, M=54790582200en_US
dc.identifier.scopusauthoridOoi, GC=7006176119en_US
dc.identifier.scopusauthoridHui, DS=7101862411en_US
dc.identifier.scopusauthoridHo, PL=7402211363en_US
dc.identifier.scopusauthoridTsang, KW=7201555024en_US
dc.identifier.issnl1027-3719-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats